Asthma Treatment Global Market Report 2026

Asthma treatment involves the medical care and management approaches used to control and ease asthma symptoms, prevent asthma attacks, and improve overall lung function in affected individuals. These treatments help reduce airway inflammation and manage symptoms, allowing individuals to breathe more comfortably.

The main types of asthma treatment include long-term control medications and quick-relief medications. Long-term control medications are taken on a daily basis to maintain asthma control and prevent the onset of symptoms. The device types used include inhalers, dry powder devices, metered-dose inhalers, and soft mist nebulizers. The key drug classes involved are short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), leukotriene modifiers, immunomodulators, combination drugs, and others. These treatments are administered through various routes such as oral, inhaled, intravenous, and subcutaneous, and are distributed through channels including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

Tariffs have impacted the asthma treatment market by raising costs for imported inhalers, nebulizers, and active pharmaceutical ingredients (APIs) used in medications. Segments such as metered-dose inhalers and biologics are particularly affected, with regions like Asia-Pacific and Europe facing higher import duties. This has led to increased treatment costs and potential supply chain delays. On the positive side, tariffs have encouraged local manufacturing, investment in domestic production of APIs, and innovation in cost-effective asthma management solutions.

The asthma treatment market research report is one of a series of new reports from The Business Research Company that provides asthma treatment market statistics, including asthma treatment industry global market size, regional shares, competitors with a asthma treatment market share, detailed asthma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the asthma treatment industry. This asthma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The asthma treatment market size has grown steadily in recent years. It will grow from $23.75 billion in 2025 to $24.86 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to increasing prevalence of asthma globally, reliance on short-acting beta-agonists (saba), limited awareness of long-term control medications, conventional inhaler adoption, growing hospital pharmacy networks.

The asthma treatment market size is expected to see steady growth in the next few years. It will grow to $29.49 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to development of novel biologics and ltra therapies, adoption of digital inhalers and smart monitoring systems, expansion of online pharmacy distribution, increasing awareness of combination therapies, rising investment in personalized medicine and patient adherence programs. Major trends in the forecast period include rising adoption of biologics and targeted therapies, increased use of combination drugs for asthma management, growth in home-based and remote monitoring devices, expansion of online and retail pharmacy channels, focus on personalized asthma management plans.

The increasing prevalence of respiratory disorders is anticipated to drive the growth of the asthma treatment market in the coming years. Respiratory disorders encompass a range of conditions that affect lung function and breathing, including chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The growing incidence of respiratory disorders is largely linked to air pollution, as exposure to particulate matter and nitrogen oxides irritates and inflames the airways, resulting in breathing difficulties and triggering or aggravating conditions such as asthma. The rise in respiratory disorders is increasing demand for asthma treatment, which includes medications, inhalers, and lifestyle modifications to manage airway inflammation and control symptoms. For instance, in December 2023, according to the National Library of Medicine, a US-based national library, projections indicate that by 2050, COPD cases in low- and middle-income countries will more than double compared to those in high-income nations, with sub-Saharan Africa expected to experience a 59% increase and become the global leader in COPD prevalence and case numbers by 2040. Therefore, the rising prevalence of respiratory disorders is contributing to the growth of the asthma treatment market.

Major companies operating in the asthma treatment market are concentrating on the development of innovative therapies, such as anti-inflammatory rescue inhalers, to deliver rapid symptom relief while also addressing the underlying airway inflammation in asthma patients. Anti-inflammatory rescue inhalers are designed to provide immediate relief from asthma symptoms while simultaneously reducing airway inflammation during an asthma episode. For instance, in January 2024, AstraZeneca, a UK-based biopharmaceutical company, introduced AIRSUPRA (albuterol/budesonide), an innovative asthma inhaler. AIRSUPRA is the first and only US Food and Drug Administration-approved fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), formulated as a rescue medication for asthma. It delivers rapid bronchodilation while concurrently targeting airway inflammation during asthma exacerbations, addressing both symptoms and underlying inflammation with a single inhalation. The inhaler is indicated for adults aged 18 years and older and supports improved overall asthma control while reducing dependence on separate controller therapies.

In January 2024, GSK plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed sum. Through this acquisition, GSK aims to strengthen its respiratory treatment portfolio and support long-term growth by combining Aiolos Bio's innovative asthma therapies with GSK's global development and commercialization capabilities. Aiolos Bio is a US-based clinical-stage biopharmaceutical company focused on asthma treatment.

Major companies operating in the asthma treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Genentech Inc., Chiesi Farmaceutici S.p.A., Cipla Limited.

North America was the largest region in the asthma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the asthma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma treatment market consists of revenues earned by entities by providing services such as diagnosis, medication administration, inhalation therapy, monitoring, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma treatment market also includes sales of nebulizers, leukotriene modifiers, corticosteroids, and bronchodilators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Asthma Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses asthma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for asthma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The asthma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment: Long-Term Control Medications; Quick-Relief Medications
• 2) By Device Type: Inhalers; Dry Powder; Metered Dose; Soft Mist Nebulizers
• 3) By Drug Class: Short-Acting Beta-Agonists (SABA); Long-Acting Beta-Agonists (LABA); Inhaled Corticosteroids (ICS); Leukotriene Modifiers; Immunomodulators; Combination Drugs; Other Drug Class
• 4) By Route Of Administration: Oral; Inhaled; Intravenous; Subcutaneous
• 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Long-Term Control Medications: Inhaled Corticosteroids (ICS); Long-Acting Beta-Agonists (LABA); Leukotriene Receptor Antagonists (LTRA); Long-Acting Muscarinic Antagonists (LAMA); Methylxanthines; Biologics
• 2) By Quick-Relief Medications: Short-Acting Beta-Agonists (SABA); Systemic Corticosteroids; Anticholinergics
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; AstraZeneca PLC; GlaxoSmithKline plc; Amgen Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Limited; Regeneron Pharmaceuticals Inc.; Sun Pharmaceutical Industries Limited; Genentech Inc.; Chiesi Farmaceutici S.p.A.; Cipla Limited.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.